|GenoMed Treats Its First Presumptive West Nile Virus Patient of 2005|
Contact: David Moskowitz MD GenoMed, Inc. tel. 314-983-9933 email@example.com
ST. LOUIS--June 16, 2005--GenoMed Inc.-- ("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets Symbol: GMED) a St. Louis, Missouri-based Next Generation Disease Management company, announced today that it has successfully treated its first patient this summer with presumed West Nile virus encephalitis.
The patient is a previously healthy 17 year old woman in Philadelphia, PA, whose parents called GenoMed yesterday from her hospital room. Their daughter had been agitated with a fever for three days. Bacterial meningitis had been ruled out by the hospital staff with a spinal tap. Her parents called GenoMed when she became delirious, and could no longer recognize them, despite being on antiviral medications. A family member had found out about GenoMed's clinical trial for West Nile virus on the Internet.
After two doses on GenoMed's protocol, 12 hours apart, the patient's mental state has improved markedly, according to her mother. She could recognize her parents, could tell her mother that she felt hot and thirsty, and has been sleeping quietly.
Said Dr. Moskowitz, GenoMed's CEO and Chief Medical Officer, "This patient's medical team diagnosed viral encephalitis. It will take a week or two to establish whether or not it's West Nile virus encephalitis. But since our treatment approach should work for most viruses, we could initiate treatment empirically. We're extremely gratified that her family turned to us, and even more excited that the patient has responded so quickly, as we've seen in previous summers."
The patient's doctors had told her parents to be prepared for her to remain delirious or in a coma for two to three weeks.
Physicians in Stanislaus County, California are now rushing GenoMed's WNV protocol to the local Institutional Review Board for use in their residents.
To enroll in GenoMed's trial, which uses already existing, safe medication present in every drug store and hospital, just go to www.genomed.com and click on the link for the West Nile virus trial.
GenoMed has found what it believes to be the "master" disease gene, and has already been able to prevent kidney failure due to diabetes and hypertension in whites, blacks and Hispanics; dramatically delay the progression of terminal emphysema; and begin to see success in treating autoimmune diseases, West Nile virus encephalitis, and cancer. GenoMed's broad-spectrum anti-viral approach was specifically mentioned in BioShield II, recently introduced in the US Senate. GenoMed has recently found several thousand genes for the top six solid cancers in Caucasians--breast, colon, lung, ovarian, pancreatic, and prostate--and is currently offering its Healthchip(r) for early diagnosis of cancer on a research basis.